Clinical trials: High Triglycerides
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.
- Trial name
- NCT01849497
- Testing
- Evolocumab Pre-filled Syringe, Evolocumab AI/pen
- Where
- 26 sites in United States, Canada
- Volunteers
- 149 people
- Sponsor
- Amgen
Severe Hypertriglyceridemia
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly [QW] or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in…
- Trial name
- NCT04541186
- Testing
- Pegozafermin
- Where
- 48 sites in United States, Czechia and 2 more
- Volunteers
- 86 people
- Sponsor
- 89bio, Inc.
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
- Trial name
- INDIGO-1 (NCT02944383)
- Testing
- Gemcabene
- Where
- 49 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Non-alcoholic Steatohepatitis, Hypertriglyceridemia
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects…
- Conditions
- Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
- Trial name
- NCT02681055
- Testing
- MN-001
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
- Trial name
- NCT03001817
- Testing
- K-877, Fenofibrate
- Where
- 220 sites in United States, Belarus and 7 more
- Volunteers
- 551 people
- Sponsor
- Kowa Research Institute, Inc.
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01335997
- Testing
- ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM)
- Volunteers
- 1,139 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, AIDS
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia.
- Conditions
- HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
- Trial name
- NCT00346697
- Testing
- Omega-3 fatty acid administration
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brown, Todd, M.D., Ph.D.
Dyslipidemia
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor.
- Trial name
- CENTAUR (NCT00728910)
- Testing
- Atorvastatin, ABT335, ER Niacin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
Hypertriglyceridemia
Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia
The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia…
- Trial name
- NCT01350999
- Testing
- omega-3-acid ethyl esters 90 (TAK-085), Eicosapentaenoic acid-ethyl (EPA)
- Volunteers
- 503 people
- Sponsor
- Takeda
Lipid Disorder, Triglycerides High
Vascepa to Accelerate Lipoprotein Uptake and Elimination
This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual…
- Conditions
- Lipid Disorder, Triglycerides High, Dyslipidemias
- Trial name
- VALUE (NCT03885661)
- Testing
- Icosapent Ethyl 1000 MG [Vascepa]
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hypertriglyceridemia, Type 2 Diabetes
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes
- Trial name
- TRIAGE (NCT04365400)
- Testing
- DS102
- Where
- 56 sites in United States, Georgia and 4 more
- Volunteers
- 233 people
- Sponsor
- Afimmune
Hypertriglyceridemia, Cardiovascular Diseases
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03385239
- Testing
- ISIS 678354
- Where
- 31 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Akcea Therapeutics
Hyperlipidemia, Healthy
Effects of Omega-3 Fatty Acids on the Human Gene Expression
The aim of this study is to investigate the effects of short- and long-term intervention with EPA and DHA-rich fish oil on gene expression profiles in healthy and hyperlipidemic males.
- Trial name
- NCT01089231
- Testing
- Fish oil
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gottfried Wilhelm Leibniz Universität Hannover
Hypertriglyceridemia
Efficacy of TAK-085 in Participants With Hypertriglyceridemia
The purpose of this study was to determine the efficacy and safety of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia…
- Trial name
- NCT01350973
- Testing
- Omega-3-acid ethyl esters 90 (TAK-085), Eicosapentaenoic acid-ethyl (EPA-E)
- Volunteers
- 611 people
- Sponsor
- Takeda
Hypertriglyceridemia
Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides
The investigators will conduct a randomized clinical trial to evaluate the efficacy of Lovaza (formerly known as Omacor) in reducing triglyceride levels in youth ages 10-19 years old whose baseline triglycerides range from 150…
- Trial name
- NCT00672633
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Boston Children's Hospital
High Triglyceride Level, HIV Infection
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
The study seeks to determine if the use of omega three fatty acids in individuals infected with HIV and with high triglycerides leads to improved triglyceride levels, better blood vessel function and decrease in the amount of…
- Trial name
- HOST (NCT01041521)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Tufts University
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Hypertriglyceridemia, Diabetic Neuropathy
Lovaza® and Microvascular Function in Type 2 Diabetes
The objective of this study is to determine the efficacy of 6 months of 4 g/day oral Lovaza® on endothelial-dependent and heat-induced vasodilation in type 2 diabetics with neuropathy and elevated triglyceride levels.
- Trial name
- NCT00931879
- Testing
- omega-3-ethyl esters
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Eastern Virginia Medical School
Severe Hypertriglyceridemia
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
- Trial name
- SHASTA-2 (NCT04720534)
- Testing
- ARO-APOC3
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 229 people
- Sponsor
- Arrowhead Pharmaceuticals
Dyslipidemia
Study of Trilipix Effects on Lipids and Arteries
Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high…
- Trial name
- NCT01025492
- Testing
- Trilipix
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Utah